SCHEMBL5569560

SCHEMBL5569560

Cc1nc2c3c(c(C(=O)N(C)C)cn2c1C)CCC(c1ccc(F)cc1)O3

nearest known ligand 0.35

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ATP4A P20648 1/20 0.35
ATP4B P51164 1/20 0.35
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
MCHR1 Q99705 1/20 0.32
HTR7 P34969 1/20 0.32
CYP3A4 P08684 1/20 0.31
CYP2C9 P11712 1/20 0.31
TSHR P16473 1/20 0.30
JAK2 O60674 1/20 0.30
NTRK1 P04629 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5570722 1.00 ATP4A (0.35) ATP4AATP4BKDM4EMEN1ALDH1A1
SCHEMBL5566474 1.00 ATP4A (0.35) ATP4AATP4BKDM4EMEN1ALDH1A1
SCHEMBL5566826 0.90 ATP4A (0.43) ATP4AATP4BKDM4EMEN1ALDH1A1
SCHEMBL5567312 0.90 ATP4A (0.43) ATP4AATP4BKDM4EMEN1ALDH1A1
SCHEMBL4888725 0.90 ATP4A (0.43) ATP4AATP4BKDM4EMEN1ALDH1A1
SCHEMBL5569811 0.85 RIPK1 (0.41) ATP4AATP4BCYP3A4CYP2C9JAK2
SCHEMBL5570783 0.85 RIPK1 (0.41) ATP4AATP4BCYP3A4CYP2C9JAK2
SCHEMBL5571355 0.83 CYP3A4 (0.33) ATP4AATP4BMEN1KMT2ACYP3A4
SCHEMBL5569799 0.83 CYP3A4 (0.33) ATP4AATP4BMEN1KMT2ACYP3A4
SCHEMBL5566402 0.83 CYP3A4 (0.33) ATP4AATP4BMEN1KMT2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070066674-A1 Tricyclic imidzopyridines for use as gastric secretion inhibitors ALTANA PHARMA AG (DE) 2007-03-22 US disclosed
EP-1696921-A1 TRICYCLIC IMIDAZOPYRIDINES FOR USE AS GASTRIC SECRETION INHIBITORS Altana Pharma AG (DE) 2006-09-06 EP disclosed
WO-2005058325-A1 TRICYCLIC IMIDAZOPYRIDINES FOR USE AS GASTRIC SECRETION INHIBITORS ALTANA PHARMA AG (DE) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066674-A1 Tricyclic imidzopyridines for use as gastric secretion inhibitors GIPR, SLC10A2, GRPR ATP4A 96/4885ATP4B 259/4885KDM4E 4244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.